Trio, Ajinomoto to develop cancer therapeutic

By The Science Advisory Board staff writers

May 1, 2020 -- Cancer therapeutics company Trio Pharmaceuticals and biopharmaceutical contract development and manufacturing company Ajinomoto Bio-Pharma Services have announced a partnership to develop cancer therapeutics.

Through the partnership, Ajinomoto Bio-Pharma will use its AJICAP site-specific technology to conjugate a cytotoxic payload to Trio's lead oncology candidate. Trio will then evaluate the functionality of the Triobody Drug Conjugate (TDC), an antibody-drug conjugation that targets tumor growth and immunosuppression.

Scientists use antibodies to build nanostructures
Researchers from the University of Rome, Tor Vergata demonstrate a new model to control the construction of nanostructures using antibodies. The findings...
Personalized cancer vaccines now possible due to discovery of cancer frameshift neoantigens
Researchers from Arizona State University's Biodesign Institute demonstrated experimental proof-of-concept that cancer mutations produce individual neoantigens,...
Vaccine in development against hypervirulent Klebsiella
Concerns arising over the development of hypervirulent strains of Klebsiella pneumoniae have led researchers to develop an entirely new vaccine to protect...
Success of immunotherapies increased in cancer patients through co-treatment with monoclonal antibodies
A new approach provides evidence that it is possible to break down the protective wall surrounding tumor cells, therefore making immunotherapies more...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter